Aclaris Therapeutics to Announce Second Quarter 2019 Financial Results on August 8, 2019
01 août 2019 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today...
Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint
30 juil. 2019 16h01 HE
|
Aclaris Therapeutics, Inc.
ATI-501 achieved statistically significant improvement over placebo in several measures of hair growth, including the primary endpoint and certain secondary endpoints of the trial.ATI-501 was...
Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1%
09 juil. 2019 07h00 HE
|
Aclaris Therapeutics, Inc.
Issuance of U.S. Patent No. 10,335,391 Further Strengthens Aclaris’ RHOFADE Patent Portfolio WAYNE, Pa., July 09, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led...
Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors
03 juil. 2019 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., July 03, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today...
Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints
26 juin 2019 16h01 HE
|
Aclaris Therapeutics, Inc.
ATI-502 did not achieve statistical superiority at the primary or secondary endpoints due to high rates of disease resolution in vehicle-treated patients WAYNE, Pa., June 26, 2019 (GLOBE NEWSWIRE)...
Aclaris Therapeutics Announces Positive 6-Month Results from a Phase 2 Open-Label Clinical Trial of ATI-502 Topical in Patients with Androgenetic Alopecia (Male/Female Pattern-Baldness)
17 juin 2019 06h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., June 17, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today...
Aclaris Therapeutics to Present at the 2019 JMP Securities Life Sciences Conference
14 juin 2019 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., June 14, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today...
Aclaris Therapeutics to Present at Jefferies 2019 Global Healthcare Conference
24 mai 2019 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., May 24, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today...
Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments
08 mai 2019 16h01 HE
|
Aclaris Therapeutics, Inc.
Submitted IND for ATI-450, an oral MK2 inhibitorRHOFADE net sales of $3.7 million for the first quarter of 2019Management to Host Conference Call at 5:00 PM ET today WAYNE, Pa., May 08, 2019 (GLOBE...
Aclaris Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019
01 mai 2019 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., May 01, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today...